Biocan novel DHPPI/L4, Lyophilisate and solvent for suspension for injection for dogs
Canine live vaccine against parvovirosis, distemper, inf. hepatitis, inf. laryngotracheitis and parainfluenza and inactivated liquid vaccine against four serovars of leptospirosis.
Composition per 1 ml dose:
Lyophilisate (live attenuated):
Canine Distemper virus, strain CDV Bio 11/A - min. 103.1 TCID50*, max. 105.1 TCID50*
Canine Adenovirus Type 2, strain CAV-2 Bio 13 - min. 103.6 TCID50**, max. 105.3 TCID50*
Canine Parvovirus Type 2b, strain CPV-2b Bio 12/B - min. 104.3 TCID50*, min. 106.6 TCID50*
Canine Parainfluenza Type 2virus, strain CPiV-2 Bio 15 - min. 103.1 TCID50*, max. 105.1 TCID50*
Solvent (inactivated):
Leptospira interrogans serogroup Icterohaemorrhagiae, serovar icterohaemorrhagiae, strain MSLB 1089 GMT** ≥ 1:51 ALR***
Leptospira interrogans serogroup canicola, serovar canicola, strain MSLB 1090 GMT** ≥ 1:51 ALR***
Leptospira kirschneri serogroup grippotyphosa, serovar grippotyphosa, strain MSLB 1091 GMT** ≥ 1:40 ALR***
Leptospira interrogans serogroup australis, serovar bratislava, strain MSLB 1088 GMT** ≥ 1:51 ALR***
Adjuvant: aluminium hydroxide (quantified as Al2O3) 1.8-2.2 mg
* Tissue culture infectious dose – 50%
** Geometric mean titre
*** Antibody micro agglutination-lytic reaction
Indications:
Active immunization of dogs from 6 weeks of age.
- to prevent mortality and clinical signs caused by canine distemper virus
- to prevent mortality and clinical signs caused by canine adenovirus type 1
- to prevent clinical signs and reduce viral excretion caused by canine adenovirus type 2
- to prevent clinical signs, leukopenia and viral excretion caused by canine parvovirus
- to prevent clinical signs (nasal and ocular discharge) and reduce viral excretion caused by canine parainfluenza virus
- to prevent clinical signs, infection and urinary excretion caused by L.interrogans serogroup Australis serovar Bratislava
- to prevent clinical signs and urinary excretion and reduce infection caused by L.interrogans serogroup Canicola serovar Canicola and L. interrogans serogroup Icterhaemorrhagiae serovar Icterohaemorrhagiae
- to prevent clinical signs and reduce infection and urinary excretion caused by L. kirschneri serogroup Grippotyphosa serovar Grippotyphosa
Onset of immunity:
- 3 weeks after the first vaccination for CDV, CAV, CPV,
- 3 weeks after completion of the primary course for CPiV and
- 4 weeks after completion of the primary course for Leptospira components.
Duration of immunity:
At least three years following the primary vaccination course for canine distemper virus, canine adenovirus type 1, canine adenovirus type 2 and canine parvovirus. At least one year following the primary vaccination course for canine parainfluenza virus and Leptospira components.
The duration of immunity against CAV-2 was not established by challenge. It was shown that 3 years after the vaccination CAV-2 antibodies are still present. Protective immune response against CAV-2 associated respiratory disease is considered to last at least 3 years.
Target species
Dog
Bioveta